• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by NexImmune Inc.

    8/2/24 4:05:57 PM ET
    $NEXI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NEXI alert in real time by email
    DEFA14A 1 d793442ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☐

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    NexImmune, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     


    LOGO

    9119 Gaither Road

    Gaithersburg, MD 20877

    August 2, 2024

    Notice of Adjournment of Special Meeting of Stockholders

    Dear Stockholder:

    The Special Meeting of Stockholders (the “Special Meeting”) for NexImmune, Inc. (the “Company”) was reconvened on August 2, 2024 and has been adjourned to August 9, 2024 at 10:00 a.m., Eastern Time, to be held virtually via live webcast on the Internet. The close of business on June 11, 2024 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Special Meeting.

    The Proxy Statement we sent you in June 2024 contains important information regarding the proposal to approve the liquidation and dissolution of the Company and the Plan of Liquidation and Dissolution that all stockholders are being asked to consider. A copy of the Proxy Statement may be viewed or downloaded by following the instructions at www.proxyvote.com. If you have any questions regarding the proposals, or need assistance with voting, you may call Laurel Hill Advisory Group, LLC, the Company’s proxy solicitor, toll-free at 1-888-742-1305.

    If you are the record holder of your shares, you may vote in one of four ways. You may submit a proxy to vote over the Internet, by telephone, or by mail or you may vote at the Special Meeting.

    You may submit a proxy to vote over the Internet or by telephone: Follow the instructions included in the Notice or, if you received printed materials, in the proxy card to vote by Internet or telephone.

    You may submit a proxy to vote by mail: If you received a proxy card by mail, you can vote by mail by completing, signing, dating and returning the proxy card as instructed on the card.

    You may vote during the meeting: If you attend the Special Meeting, you may participate in and vote online at the Special Meeting. You will need to enter your 16-digit control number to vote your shares at the Special Meeting. Please visit www.virtualshareholdermeeting.com/NEXI2024SM2 for instructions on how to attend the Special Meeting live over the Internet. To vote during the Special Meeting when the polls open use the “vote” button on the interface.

    Telephone and Internet voting for stockholders of record will be available until 11:59 p.m. Eastern Time on August 8, 2024 and mailed proxy cards must be received by August 8, 2024 in order to be counted at the Special Meeting. If the Special Meeting is adjourned or postponed, these deadlines may be extended.

    Thank you for your prompt attention to this matter and your continued confidence in NexImmune, Inc. If you have already voted, we appreciate your participation, and you may disregard this notice.

    Sincerely,

    Sol J. Barer, Ph.D.

    Chairman of the Board of Directors

    Get the next $NEXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEXI

    DatePrice TargetRatingAnalyst
    2/22/2022$21.00 → $13.00Outperform
    Raymond James
    11/15/2021$30.00 → $21.00Outperform
    Raymond James
    More analyst ratings

    $NEXI
    Financials

    Live finance-specific insights

    See more
    • NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

      Company has initiated pre-IND discussions with the FDA for its first AIM INJ indicationNEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed; Company continues to follow patients and will announce data at or around an upcoming scientific conferenceCompany announces executive management changes as part of resource reallocation GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells for liquid and solid malignancies, today reported financial results for t

      3/28/23 4:01:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update

      Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseasesInitiating a corporate resource reallocation to advance the AIM INJ platform, reduce operating expenses and extend cash runway through the third quarter of 2023 Pausing enrollment and initiation for the NEXI-001 and NEXI-003 trials, respectively, and pursuing external clinical development through potential academic and corporate partners GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted

      11/14/22 4:01:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

      Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company's first solid tumor product candidate for the treatment of HPV-related cancersPlans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H22Clinical updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 4Q22Company is prioritizing resources to support Company's lead product candidates, NEXI-001 and NEXI-003 GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed t

      8/15/22 4:05:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Leadership Updates

    Live Leadership Updates

    See more
    • NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

      Clinical data updates for the Company's two lead product candidates in Phase 1/2 clinical trials expected in 2H2022Investigational New Drug (IND) submission for NEXI-003, the Company's first product for solid tumors, planned for 1H2022Plans to report additional preclinical and IND enabling data for the AIM Injectable platform in 2H2022 GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported financial results for the first quarter of 2022. "This quarter, we hav

      5/12/22 4:01:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

      GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director. "I am honored to join the board of NexImmune at this pivotal juncture in the Company's work," stated Dr. Gandhi. "I am excited to work with NexImmune's leadership on maximizing the potential of its novel technology in multip

      5/10/22 7:30:00 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors

      GAITHERSBURG, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones has been appointed as the Company's Chief Executive Officer and a member of its Board of Directors. Her appointment follows the departure of Scott Carmer, who submitted his letter of resignation this week.  "The Board is pleased to appoint Kristi Jones as our new Chief Executive Officer and member of the Board of Directors," said Sol J. Barer, Chairman of NexImmune's Board of Directors.

      2/17/22 4:15:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      GAITHERSBURG, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 304,731 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warra

      2/6/24 4:42:41 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

      GAITHERSBURG, Md., Feb. 02, 2024 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced that it has entered into a definitive agreement with a single healthcare focused institutional investor for the issuance and sale of an aggregate of 304,731 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $12.05 per share (or per common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq ru

      2/2/24 2:00:00 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

      A JDRF funded grant is being used to explore the combination of NexImmune's antigen specific nanoparticles and an anti-CD3 mAb for prevention and treatment of type 1 diabetes GAITHERSBURG, Md., Oct. 24, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (NASDAQ:NEXI) announces the extension of the research partnership between NexImmune, Yale and JDRF to explore the use of NexImmune's AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells. The extension includes an additional $300,000 grant, funded by JDRF to Yale, as a part of its Cures research portfolio, which includes therapies for the prevention of type 1 diabetes (T1D). "We

      10/24/23 8:00:00 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James reiterated coverage on NexImmune with a new price target

      Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $13.00 from $21.00 previously

      2/22/22 4:56:18 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James reiterated coverage on NexImmune with a new price target

      Raymond James reiterated coverage of NexImmune with a rating of Outperform and set a new price target of $21.00 from $30.00 previously

      11/15/21 7:53:18 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on NexImmune with a new price target

      Raymond James initiated coverage of NexImmune with a rating of Outperform and set a new price target of $30.00

      4/1/21 6:58:11 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Jones Kristi bought $0 worth of Series A Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - NexImmune, Inc. (0001538210) (Issuer)

      6/13/24 7:58:48 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    SEC Filings

    See more
    • SEC Form 25-NSE filed by NexImmune Inc.

      25-NSE - NexImmune, Inc. (0001538210) (Subject)

      9/6/24 7:41:13 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by NexImmune Inc.

      EFFECT - NexImmune, Inc. (0001538210) (Filer)

      8/29/24 12:15:04 AM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by NexImmune Inc.

      S-8 POS - NexImmune, Inc. (0001538210) (Filer)

      8/27/24 4:10:49 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by NexImmune Inc.

      SC 13D - NexImmune, Inc. (0001538210) (Subject)

      4/7/23 4:16:57 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NexImmune Inc. (Amendment)

      SC 13G/A - NexImmune, Inc. (0001538210) (Subject)

      2/13/23 4:16:55 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by NexImmune Inc. (Amendment)

      SC 13G/A - NexImmune, Inc. (0001538210) (Subject)

      2/13/23 4:16:55 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NEXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Jones Kristi bought $0 worth of Series A Preferred Stock (1 units at $0.01) (SEC Form 4)

      4 - NexImmune, Inc. (0001538210) (Issuer)

      6/13/24 7:58:48 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Marchio Albert N Ii

      3 - NexImmune, Inc. (0001538210) (Issuer)

      4/10/24 5:13:29 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roemer Alan S. sold $16,045 worth of shares (7,825 units at $2.05), closing all direct ownership in the company (SEC Form 4)

      4 - NexImmune, Inc. (0001538210) (Issuer)

      11/22/23 5:18:01 PM ET
      $NEXI
      Biotechnology: Pharmaceutical Preparations
      Health Care